Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Monzo

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Journal of Hypertension|October 5, 2019
Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trialLuca Monzo, João Pedro Ferreira, Paula Abreu, et al.
European Journal of Heart Failure|March 20, 2026
Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adultsLuca Monzo, Olivier Huttin, Emmanuel Bresso, et al.
European Journal of Heart Failure|August 11, 2025
A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trialJames E Udelson, Steven R Goldsmith, Daniel Burkhoff, et al.
European Journal of Heart Failure|December 10, 2024
Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fractionLuca Monzo, Emmanuel Bresso, Kenneth Dickstein, et al.
European Journal of Heart Failure|November 27, 2025
Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus documentLuca Monzo, Gianluigi Savarese, Wilfried Mullens, et al.
Journal of the American Heart Association|March 13, 2026
Hyaluronan and Syndecan-1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection FractionEstela Rocha-Oliveira, Jeremy Lagrange, Mohammad Jahangiri, et al.
Nature Cardiovascular Research|March 5, 2026
Strategies to improve regional representation in heart failure randomized controlled clinical trialsGuillaume Baudry, Luca Monzo, Rebecca A V Newton, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 21, 2020
Dysregulation of epicardial adipose tissue in cachexia due to heart failure: the role of natriuretic peptides and cardiolipinPetra Janovska, Vojtech Melenovsky, Michaela Svobodova, et al.
Journal of Cardiac Failure|December 20, 2023
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF TrialLuca Monzo, Nicolas Girerd, João Pedro Ferreira, et al.
Heart Failure Reviews|April 15, 2026
Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tieMatteo Busti, Mario Enrico Canonico, Kalliopi Keramida, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Journal of Hypertension|October 5, 2019
Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trialLuca Monzo, João Pedro Ferreira, Paula Abreu, et al.
European Journal of Heart Failure|March 20, 2026
Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adultsLuca Monzo, Olivier Huttin, Emmanuel Bresso, et al.
European Journal of Heart Failure|August 11, 2025
A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trialJames E Udelson, Steven R Goldsmith, Daniel Burkhoff, et al.
European Journal of Heart Failure|December 10, 2024
Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fractionLuca Monzo, Emmanuel Bresso, Kenneth Dickstein, et al.
European Journal of Heart Failure|November 27, 2025
Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus documentLuca Monzo, Gianluigi Savarese, Wilfried Mullens, et al.
Journal of the American Heart Association|March 13, 2026
Hyaluronan and Syndecan-1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection FractionEstela Rocha-Oliveira, Jeremy Lagrange, Mohammad Jahangiri, et al.
Nature Cardiovascular Research|March 5, 2026
Strategies to improve regional representation in heart failure randomized controlled clinical trialsGuillaume Baudry, Luca Monzo, Rebecca A V Newton, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 21, 2020
Dysregulation of epicardial adipose tissue in cachexia due to heart failure: the role of natriuretic peptides and cardiolipinPetra Janovska, Vojtech Melenovsky, Michaela Svobodova, et al.
Journal of Cardiac Failure|December 20, 2023
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF TrialLuca Monzo, Nicolas Girerd, João Pedro Ferreira, et al.
Heart Failure Reviews|April 15, 2026
Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tieMatteo Busti, Mario Enrico Canonico, Kalliopi Keramida, et al.
Pageof 12